[
  {
    "ts": null,
    "headline": "Amgen’s Weight-Loss Drug Shows Promise With Less Frequent Dosing",
    "summary": "Amgen reported early Phase 2 data suggesting patients kept weight off with less frequent dosing, a potential differentiator from Eli Lilly and Novo Nordisk.",
    "url": "https://finnhub.io/api/news?id=2e96d36c64fc6d1861ba3195c8158701ef3c48a440537ddb742cbdee3f0525dd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768513200,
      "headline": "Amgen’s Weight-Loss Drug Shows Promise With Less Frequent Dosing",
      "id": 138137483,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Amgen reported early Phase 2 data suggesting patients kept weight off with less frequent dosing, a potential differentiator from Eli Lilly and Novo Nordisk.",
      "url": "https://finnhub.io/api/news?id=2e96d36c64fc6d1861ba3195c8158701ef3c48a440537ddb742cbdee3f0525dd"
    }
  },
  {
    "ts": null,
    "headline": "Dow Jones Futures: Market Fades Despite Taiwan Semi, Goldman Lifting Chips, Banks",
    "summary": "The stock market rallied Thursday on Taiwan Semiconductor and Goldman Sachs earnings, but pared gains substantially.",
    "url": "https://finnhub.io/api/news?id=917bdf69a360317dbb96fbd2a1d422401a6622cd515179b8f8ee38dc79e9f100",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768512929,
      "headline": "Dow Jones Futures: Market Fades Despite Taiwan Semi, Goldman Lifting Chips, Banks",
      "id": 138132274,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The stock market rallied Thursday on Taiwan Semiconductor and Goldman Sachs earnings, but pared gains substantially.",
      "url": "https://finnhub.io/api/news?id=917bdf69a360317dbb96fbd2a1d422401a6622cd515179b8f8ee38dc79e9f100"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Softer Late Afternoon",
    "summary": "Health care stocks declined late Thursday afternoon, with the NYSE Health Care Index and the State S",
    "url": "https://finnhub.io/api/news?id=61977f570a0a3f8001f5ae267595ad58928abde04dd09ca3de1cceb79c925a09",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768509542,
      "headline": "Sector Update: Health Care Stocks Softer Late Afternoon",
      "id": 138132320,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Health care stocks declined late Thursday afternoon, with the NYSE Health Care Index and the State S",
      "url": "https://finnhub.io/api/news?id=61977f570a0a3f8001f5ae267595ad58928abde04dd09ca3de1cceb79c925a09"
    }
  },
  {
    "ts": null,
    "headline": "State Street's crypto push, FDA delays review of Eli Lilly GLP-1",
    "summary": "Yahoo Finance Host Josh Lipton tracks today's top moving stocks and biggest market stories in this Market Minute, including State Street's (STT) push into crypto and tokenized assets products and healthcare stocks Eli Lilly (LLY), Sanofi (SNY), and Disc Medicine (IRON) after Reuters reports the US Food and Drug Administration (FDA) delayed its review for several drugs. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.",
    "url": "https://finnhub.io/api/news?id=a0c51ec05c2678e2f3123b5e000712b7b2d500371fb9612b705adc7d33831e4d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768504146,
      "headline": "State Street's crypto push, FDA delays review of Eli Lilly GLP-1",
      "id": 138126303,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Yahoo Finance Host Josh Lipton tracks today's top moving stocks and biggest market stories in this Market Minute, including State Street's (STT) push into crypto and tokenized assets products and healthcare stocks Eli Lilly (LLY), Sanofi (SNY), and Disc Medicine (IRON) after Reuters reports the US Food and Drug Administration (FDA) delayed its review for several drugs. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.",
      "url": "https://finnhub.io/api/news?id=a0c51ec05c2678e2f3123b5e000712b7b2d500371fb9612b705adc7d33831e4d"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Softer in Afternoon Trading",
    "summary": "Health care stocks declined Thursday afternoon, with the NYSE Health Care Index shedding 0.9% and th",
    "url": "https://finnhub.io/api/news?id=9ca942afcceb2dab0423eba065c7b6852befa216f772186a8a65d3bd45f96e6d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768502940,
      "headline": "Sector Update: Health Care Stocks Softer in Afternoon Trading",
      "id": 138126304,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Health care stocks declined Thursday afternoon, with the NYSE Health Care Index shedding 0.9% and th",
      "url": "https://finnhub.io/api/news?id=9ca942afcceb2dab0423eba065c7b6852befa216f772186a8a65d3bd45f96e6d"
    }
  },
  {
    "ts": null,
    "headline": "FDA delays Eli Lilly's weight-loss pill, Reddit stock stumbles",
    "summary": "Yahoo Finance Senior Reporter Brooke DiPalma tracks Thursday's top moving stocks and biggest market stories in this Market Minute. Eli Lilly (LLY) stock is under pressure after Reuters reported that the US Food and Drug Administration (FDA) delayed approval of the company's weight-loss pill. Reddit (RDDT) stock is sliding on an RBC analyst's remarks regarding the company's ad environment. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.",
    "url": "https://finnhub.io/api/news?id=cc1f51c00dafcf297bc802400d9c00bc489d50dfaed89ac95b500bbb7b9de555",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768500716,
      "headline": "FDA delays Eli Lilly's weight-loss pill, Reddit stock stumbles",
      "id": 138126305,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Yahoo Finance Senior Reporter Brooke DiPalma tracks Thursday's top moving stocks and biggest market stories in this Market Minute. Eli Lilly (LLY) stock is under pressure after Reuters reported that the US Food and Drug Administration (FDA) delayed approval of the company's weight-loss pill. Reddit (RDDT) stock is sliding on an RBC analyst's remarks regarding the company's ad environment. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.",
      "url": "https://finnhub.io/api/news?id=cc1f51c00dafcf297bc802400d9c00bc489d50dfaed89ac95b500bbb7b9de555"
    }
  },
  {
    "ts": null,
    "headline": "Why Eli Lilly (LLY) Stock Is Down Today",
    "summary": "Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 4.5% in the afternoon session after the U.S. Food and Drug Administration (FDA) delayed its decision on the company's new oral weight-loss pill, Orforglipron. The regulator pushed its decision date to April 10 from a prior expectation of late-March. Markets often react negatively to such postponements as they delay a product's market launch and extend uncertainty over its potential sales, which can limit revenue growth. The drug w",
    "url": "https://finnhub.io/api/news?id=4fec7f3a58c39ca12a0c20a1d6d1057e42149631a97e645b61ee368c17385d48",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768499489,
      "headline": "Why Eli Lilly (LLY) Stock Is Down Today",
      "id": 138126306,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 4.5% in the afternoon session after the U.S. Food and Drug Administration (FDA) delayed its decision on the company's new oral weight-loss pill, Orforglipron. The regulator pushed its decision date to April 10 from a prior expectation of late-March. Markets often react negatively to such postponements as they delay a product's market launch and extend uncertainty over its potential sales, which can limit revenue growth. The drug w",
      "url": "https://finnhub.io/api/news?id=4fec7f3a58c39ca12a0c20a1d6d1057e42149631a97e645b61ee368c17385d48"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk: Valuation Alone Doesn't Justify Bullishness",
    "summary": "Novo Nordisk A/S is rated a Hold with strong growth, robust fundamentals and impressive revenue and profitability. Learn more about NVO stock here.",
    "url": "https://finnhub.io/api/news?id=c757282a54c64e7f9a0bbad1f3c65d19a923bb8bfe69822c0ae5d6b6a08642f4",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768498111,
      "headline": "Novo Nordisk: Valuation Alone Doesn't Justify Bullishness",
      "id": 138134304,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1393991963/image_1393991963.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Novo Nordisk A/S is rated a Hold with strong growth, robust fundamentals and impressive revenue and profitability. Learn more about NVO stock here.",
      "url": "https://finnhub.io/api/news?id=c757282a54c64e7f9a0bbad1f3c65d19a923bb8bfe69822c0ae5d6b6a08642f4"
    }
  },
  {
    "ts": null,
    "headline": "Half of GLP-1 users ditch their injections — and some are turning to other weight-loss methods instead",
    "summary": "New research has found that 50% of patients regain the weight they lost if they stop taking Wegovy and Zepbound",
    "url": "https://finnhub.io/api/news?id=eebe177c3c4ea6e88afd8a7228f056aef53035e981c2b31d35e3ba6b323c4db3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768495860,
      "headline": "Half of GLP-1 users ditch their injections — and some are turning to other weight-loss methods instead",
      "id": 138151697,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "New research has found that 50% of patients regain the weight they lost if they stop taking Wegovy and Zepbound",
      "url": "https://finnhub.io/api/news?id=eebe177c3c4ea6e88afd8a7228f056aef53035e981c2b31d35e3ba6b323c4db3"
    }
  },
  {
    "ts": null,
    "headline": "Where is Eli Lilly and Company (LLY) Headed According to Analysts?",
    "summary": "Eli Lilly and Company (NYSE:LLY) is one of the best long term growth stocks to buy according to hedge funds. On January 9, Jefferies reaffirmed a Buy rating on Eli Lilly and Company (NYSE:LLY) and set a price target of $1,300.00. The rating update came after Eli Lilly and Company (NYSE:LLY) announced on January 8 […]",
    "url": "https://finnhub.io/api/news?id=c06dff17119e9acf6633cb7a0632b85c0f186844c48b7f53c2283ad62859e22d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768495189,
      "headline": "Where is Eli Lilly and Company (LLY) Headed According to Analysts?",
      "id": 138122641,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE:LLY) is one of the best long term growth stocks to buy according to hedge funds. On January 9, Jefferies reaffirmed a Buy rating on Eli Lilly and Company (NYSE:LLY) and set a price target of $1,300.00. The rating update came after Eli Lilly and Company (NYSE:LLY) announced on January 8 […]",
      "url": "https://finnhub.io/api/news?id=c06dff17119e9acf6633cb7a0632b85c0f186844c48b7f53c2283ad62859e22d"
    }
  },
  {
    "ts": null,
    "headline": "How Will Mounjaro and Zepbound Sales Aid LLY's Upcoming Q4 Results?",
    "summary": "Eli Lilly's Q4 revenues are expected to reflect strong Mounjaro and Zepbound demand, as supply gains and global uptake offset pricing pressure.",
    "url": "https://finnhub.io/api/news?id=490719167ba7c1533e6d34bbe917ae42f006ee33babdf88fe89b601381dfaaf5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768490220,
      "headline": "How Will Mounjaro and Zepbound Sales Aid LLY's Upcoming Q4 Results?",
      "id": 138122642,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly's Q4 revenues are expected to reflect strong Mounjaro and Zepbound demand, as supply gains and global uptake offset pricing pressure.",
      "url": "https://finnhub.io/api/news?id=490719167ba7c1533e6d34bbe917ae42f006ee33babdf88fe89b601381dfaaf5"
    }
  },
  {
    "ts": null,
    "headline": "JPM26: Eli Lilly highlights Lp(a) drugs as cardiovascular growth focus",
    "summary": "Eli Lilly highlighted elevated Lp(a) as a major unmet need within a broader cardiometabolic strategy.",
    "url": "https://finnhub.io/api/news?id=56ab584d3cd3643a69ec702f36c2e7ff9f68a0a97cbeec4de6729df3152f4e1e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768490107,
      "headline": "JPM26: Eli Lilly highlights Lp(a) drugs as cardiovascular growth focus",
      "id": 138121558,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly highlighted elevated Lp(a) as a major unmet need within a broader cardiometabolic strategy.",
      "url": "https://finnhub.io/api/news?id=56ab584d3cd3643a69ec702f36c2e7ff9f68a0a97cbeec4de6729df3152f4e1e"
    }
  },
  {
    "ts": null,
    "headline": "JPM26: Eli Lilly’s obesity drugs target commercial and governmental access",
    "summary": "Eli Lilly has further expanded its weight-loss initiatives with novel therapies such as orforglipron, an oral GLP-1 receptor agonist.",
    "url": "https://finnhub.io/api/news?id=3134b03b8d51e56e5eea2e030ab3603090e42a9aa874575e54aa6ff8f54c1a77",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768488119,
      "headline": "JPM26: Eli Lilly’s obesity drugs target commercial and governmental access",
      "id": 138121559,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly has further expanded its weight-loss initiatives with novel therapies such as orforglipron, an oral GLP-1 receptor agonist.",
      "url": "https://finnhub.io/api/news?id=3134b03b8d51e56e5eea2e030ab3603090e42a9aa874575e54aa6ff8f54c1a77"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk stock target raised at UBS ahead of Wegovy Pill launch",
    "summary": "Investing.com -- UBS raised its 12-month price target for Novo Nordisk to 390 from 295 Danish crowns, citing valuation factors and investor attention ahead of the launch of the Wegovy weight-loss pill. The bank reiterated a Neutral rating on the stock.",
    "url": "https://finnhub.io/api/news?id=80376dff77f55e8a86e68f389170379f14b5871925de12dbfac07c4d410ffaf8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768487753,
      "headline": "Novo Nordisk stock target raised at UBS ahead of Wegovy Pill launch",
      "id": 138121560,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Investing.com -- UBS raised its 12-month price target for Novo Nordisk to 390 from 295 Danish crowns, citing valuation factors and investor attention ahead of the launch of the Wegovy weight-loss pill. The bank reiterated a Neutral rating on the stock.",
      "url": "https://finnhub.io/api/news?id=80376dff77f55e8a86e68f389170379f14b5871925de12dbfac07c4d410ffaf8"
    }
  },
  {
    "ts": null,
    "headline": "Alexandria Real Estate Equities, Inc. (ARE): A Bear Case Theory",
    "summary": "We came across a bearish thesis on Alexandria Real Estate Equities, Inc. on Compounding Dividends’s Substack by TJ Terwilliger. In this article, we will summarize the bears’ thesis on ARE. Alexandria Real Estate Equities, Inc.’s share was trading at $54.64 as of January 13th. ARE’s trailing and forward P/E were 150.89 and 16.69 respectively according to Yahoo […]",
    "url": "https://finnhub.io/api/news?id=39dbfabc5568dc951e7a1073dac2053ac314c2a55a63b2ceab5f7447dbc3be9a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768483685,
      "headline": "Alexandria Real Estate Equities, Inc. (ARE): A Bear Case Theory",
      "id": 138120614,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We came across a bearish thesis on Alexandria Real Estate Equities, Inc. on Compounding Dividends’s Substack by TJ Terwilliger. In this article, we will summarize the bears’ thesis on ARE. Alexandria Real Estate Equities, Inc.’s share was trading at $54.64 as of January 13th. ARE’s trailing and forward P/E were 150.89 and 16.69 respectively according to Yahoo […]",
      "url": "https://finnhub.io/api/news?id=39dbfabc5568dc951e7a1073dac2053ac314c2a55a63b2ceab5f7447dbc3be9a"
    }
  },
  {
    "ts": null,
    "headline": "Why Merck's 32% Rally Isn't Enough to Change the Bearish View",
    "summary": "MRK is up over 32% in three months, but declining estimates, Keytruda's upcoming LOE and Gardasil declines keep the stock sell-rated.",
    "url": "https://finnhub.io/api/news?id=458b17ff156cdfe3bf97831959ed2ab8d4490169bf9393125aa0601d3ffaadc5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768483560,
      "headline": "Why Merck's 32% Rally Isn't Enough to Change the Bearish View",
      "id": 138121561,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "MRK is up over 32% in three months, but declining estimates, Keytruda's upcoming LOE and Gardasil declines keep the stock sell-rated.",
      "url": "https://finnhub.io/api/news?id=458b17ff156cdfe3bf97831959ed2ab8d4490169bf9393125aa0601d3ffaadc5"
    }
  },
  {
    "ts": null,
    "headline": "Market Chatter: Sanofi, Disc Medicine Drug Reviews Delayed as FDA Flags Safety, Efficacy Issues",
    "summary": "Sanofi (SNY) and Disc Medicine (IRON) saw reviews for their type 1 diabetes and rare blood disorder",
    "url": "https://finnhub.io/api/news?id=284ec44f089171561bb163e2870b460210b12cfa9b75984881d78d6cd52d1176",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768480887,
      "headline": "Market Chatter: Sanofi, Disc Medicine Drug Reviews Delayed as FDA Flags Safety, Efficacy Issues",
      "id": 138120615,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Sanofi (SNY) and Disc Medicine (IRON) saw reviews for their type 1 diabetes and rare blood disorder",
      "url": "https://finnhub.io/api/news?id=284ec44f089171561bb163e2870b460210b12cfa9b75984881d78d6cd52d1176"
    }
  },
  {
    "ts": null,
    "headline": "Stocks making the biggest moves midday: Morgan Stanley, Coinbase, Taiwan Semi, Eli Lilly & more",
    "summary": "Here are some of the names making big moves in midday trading.",
    "url": "https://finnhub.io/api/news?id=2fd941cabf33dc9dbd7660425cf5ee4dbc04a90ce6bd2c87eba6f75fbd3a4bec",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768480504,
      "headline": "Stocks making the biggest moves midday: Morgan Stanley, Coinbase, Taiwan Semi, Eli Lilly & more",
      "id": 138153447,
      "image": "https://image.cnbcfm.com/api/v1/image/108247613-1767376953496-gettyimages-2253792451-US_STOCKS.jpeg?v=1768505634&w=1920&h=1080",
      "related": "LLY",
      "source": "CNBC",
      "summary": "Here are some of the names making big moves in midday trading.",
      "url": "https://finnhub.io/api/news?id=2fd941cabf33dc9dbd7660425cf5ee4dbc04a90ce6bd2c87eba6f75fbd3a4bec"
    }
  },
  {
    "ts": null,
    "headline": "Biogen: Why I Anticipate A Difficult 2026 For 'End Of An Era' Pharma",
    "summary": "Biogen faces revenue headwinds, MS franchise erosion, underperforming launches, weak pipeline, and cost-cutting focus. Learn why BIIB stock is upgraded to sell.",
    "url": "https://finnhub.io/api/news?id=1c24417d4417286090801d483a684016a6f0f0707077f7e148a068633d184fcd",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768472026,
      "headline": "Biogen: Why I Anticipate A Difficult 2026 For 'End Of An Era' Pharma",
      "id": 138121264,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2159351618/image_2159351618.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Biogen faces revenue headwinds, MS franchise erosion, underperforming launches, weak pipeline, and cost-cutting focus. Learn why BIIB stock is upgraded to sell.",
      "url": "https://finnhub.io/api/news?id=1c24417d4417286090801d483a684016a6f0f0707077f7e148a068633d184fcd"
    }
  },
  {
    "ts": null,
    "headline": "JPM26: Novo Nordisk reshapes its strategy under new CEO",
    "summary": "Novo is positioning itself as a long‑term leader across multiple obesity segments.",
    "url": "https://finnhub.io/api/news?id=57fb3d7a71341a62c798dc92e9eb74d193c60fe93fd7ede1168aefbd1ba11c64",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768450386,
      "headline": "JPM26: Novo Nordisk reshapes its strategy under new CEO",
      "id": 138117718,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo is positioning itself as a long‑term leader across multiple obesity segments.",
      "url": "https://finnhub.io/api/news?id=57fb3d7a71341a62c798dc92e9eb74d193c60fe93fd7ede1168aefbd1ba11c64"
    }
  },
  {
    "ts": null,
    "headline": "JPM26: Eli Lilly enters 2026 with strong momentum given pipeline innovation",
    "summary": "Lilly has launched six early-stage clinical programs, and 34 discovery programs with a focus on incretins, amylins, and novel targets.",
    "url": "https://finnhub.io/api/news?id=7cec40c56978337782b6e16347c3957367d24d5a2b05152e0e9682dadf0226b6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768449898,
      "headline": "JPM26: Eli Lilly enters 2026 with strong momentum given pipeline innovation",
      "id": 138117719,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Lilly has launched six early-stage clinical programs, and 34 discovery programs with a focus on incretins, amylins, and novel targets.",
      "url": "https://finnhub.io/api/news?id=7cec40c56978337782b6e16347c3957367d24d5a2b05152e0e9682dadf0226b6"
    }
  }
]